We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
- Authors
Barry, Elly V; Vrooman, Lynda M; Dahlberg, Suzanne E; Neuberg, Donna S; Asselin, Barbara L; Athale, Uma H; Clavell, Luis A; Larsen, Eric C; Moghrabi, Albert; Samson, Yvan; Schorin, Marshall A; Cohen, Harvey J; Lipshultz, Steven E; Sallan, Stephen E; Silverman, Lewis B
- Abstract
Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity. A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's disease. We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 7, p1106
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.12.2481